pomalidomide has been researched along with adenosine in 1 studies
| Studies (pomalidomide) | Trials (pomalidomide) | Recent Studies (post-2010) (pomalidomide) | Studies (adenosine) | Trials (adenosine) | Recent Studies (post-2010) (adenosine) |
|---|---|---|---|---|---|
| 623 | 121 | 552 | 32,536 | 1,075 | 8,930 |
| Protein | Taxonomy | pomalidomide (IC50) | adenosine (IC50) |
|---|---|---|---|
| high affinity choline transporter 1 isoform a | Homo sapiens (human) | 0.3851 | |
| Sodium/nucleoside cotransporter 1 | Homo sapiens (human) | 5.5 | |
| Sodium/nucleoside cotransporter 2 | Homo sapiens (human) | 5.5 | |
| Adenosine receptor A3 | Homo sapiens (human) | 0.0011 | |
| Adenosine receptor A1 | Homo sapiens (human) | 0.0023 | |
| Equilibrative nucleoside transporter 1 | Homo sapiens (human) | 63 | |
| Solute carrier family 28 member 3 | Homo sapiens (human) | 3.3 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| van de Donk, NWCJ | 1 |
1 review(s) available for pomalidomide and adenosine
| Article | Year |
|---|---|
Immunomodulatory effects of CD38-targeting antibodies.
Topics: Adenosine; ADP-ribosyl Cyclase 1; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibody-Dependent Cell Cytotoxicity; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; B-Lymphocytes, Regulatory; B7-H1 Antigen; Humans; Immunologic Factors; Lenalidomide; Membrane Glycoproteins; Multiple Myeloma; Myeloid-Derived Suppressor Cells; Programmed Cell Death 1 Receptor; T-Lymphocytes, Regulatory; Thalidomide | 2018 |